Targeting cervical cancer: Is there a role for poly (ADP‐ribose) polymerase inhibition?

Tomao, Federica; Santangelo, Giusi; Musacchio, Lucia; Donato, Violante Di; Fischetti, Margherita; Giancotti, Antonella; Perniola, Giorgia; Petrella, Maria Cristina; Monti, Marco; Palaia, Innocenza; Muzii, Ludovico; Panici, Pierluigi Benedetti

doi:10.1002/jcp.29440

Cited by 20 publications

(10 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 Since then, several studies have been carried out to better understand genetic alterations and to evaluate the role of PARPi in other gynecological cancers, including EC. 36 Although no conclusive literature data have been yet published, clinical evidence suggests that the use of PARPi could be extremely effective in tumors with HRD. Several clinical trials showed that the deficiency of the tumor suppressor PTEN gene is associated with HR defects.…”

Section: Discussionmentioning

confidence: 99%

<p>PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives</p>

Musacchio¹,

Caruso²,

Pisano³

et al. 2020

CMAR

Self Cite

View full text Add to dashboard Cite

Advanced, recurrent and metastatic endometrial cancer (EC) has a dismal prognosis due to poor response rates to conventional treatments. In the era of precision medicine, the improved understanding of cancer genetics and molecular biology has led to the development of targeted therapies, such as poly (ADP-ribose) polymerase (PARP) inhibitors. This class of drugs that inhibit PARP enzymes has been investigated in many different types of tumors and its use in the treatment of gynecological malignancies has rapidly increased over the past few years. Data from several clinical trials showed that PARP inhibitors have a beneficial role in cancers with a defect in the homologous DNA recombination system, regardless of the BRCA mutational status. Since EC frequently shows mutations in PTEN and TP53 genes, indirectly involved in the homologous DNA recombination pathway, several in vivo and in vitro studies investigated the efficacy of PARP inhibitors in EC, showing promising results. This review will discuss the use of PARP inhibitors in endometrial cancer, summarizing data from preclinical studies and providing an overview of the ongoing trials, with a special focus on the development of combined treatment strategies with PARP inhibitors and immune checkpoint inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives</p>

Musacchio¹,

Caruso²,

Pisano³

et al. 2020

CMAR

Self Cite

View full text Add to dashboard Cite

show abstract

“…Is there a role for PARPi in these cancers? Several trials are ongoing to investigate the efficacy of PARPi in metastatic cervical (NCT03795272, NCT03476798, NCT03644342) and gastric cancers (NCT03008278; lack of OS benefit in the GOLD trial, NCT01924533) [119,120].…”

Section: Outstanding Questionsmentioning

confidence: 99%

Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications

Toh

Ngeow

2021

The Oncologist

View full text Add to dashboard Cite

Homologous recombination (HR) is a highly accurate DNA repair mechanism. Several HR genes are established cancer susceptibility genes with clinically actionable pathogenic variants (PVs). Classically, BRCA1 and BRCA2 germline PVs are associated with significant breast and ovarian cancer risks. Patients with BRCA1/BRCA2 PVs display worse clinical outcomes but respond better to platinum-based chemotherapies and PARP inhibitors, a trait termed as "BRCAness". With the advent of whole-exome sequencing and multigene panels, PVs in other HR genes are increasingly identified among familial cancers. As such, several genes such as PALB2 are reclassified as cancer predisposition genes. But, evidence for cancer risks remains unclear for many others. In this review, we will discuss the cancer predispositions and treatment implications beyond BRCA1/BRCA2, with a focus on 24 HR genes: 53BP1, ATM,

show abstract

“…Cervical cancer is the fourth most common cancer among women. About 570,000 new cases are estimated to be diagnosed each year [111]. It is also the most common gynecological cancer diagnosed in pregnancy [112].…”

Section: Claudins In Cervical Cancermentioning

confidence: 99%

“…Two major types of cervical cancer might be distinguished: squamous cell carcinoma and adenocarcinoma, of which the first one occurs more often. Human papilloma virus (HPV) infection is responsible for most of the new cervical cancer incidence, especially in countries where the screening program and vaccination are not present [111]. Although early-stage and locally-advanced cervical cancers are well cured, patients diagnosed with metastatic and recurrent cervical cancer have poor and limited treatment options [113].…”

Section: Claudins In Cervical Cancermentioning

confidence: 99%

Claudins: New Players in Human Fertility and Reproductive System Cancers

Kozieł

Kowalska

Piastowska-Ciesielska

2020

Cancers

View full text Add to dashboard Cite

Claudins are major integral proteins of tight junctions (TJs), the apical cell-cell adhesions that enable maintaining polarity of epithelial cells, their differentiation, and cell signaling. A number of studies have indicated that claudins might play a crucial role in both physiology and pathogenesis. Their tissue-specific expression was originally linked to the development of different types of cancer and triggered a hope to use them as diagnostic or prognostic markers. However, it seems that their expression is more complex than that, and undoubtedly, claudins participate in one of the most important molecular events in cells. This review summarizes the recent research evaluating the role of claudins in fertility and the most common endocrine-dependent cancers in the reproductive system and highlights the crucial role of claudins both in human fertility and the most common cancers.

show abstract

Targeting cervical cancer: Is there a role for poly (ADP‐ribose) polymerase inhibition?

Cited by 20 publications

References 51 publications

<p>PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives</p>

<p>PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives</p>

Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications

Claudins: New Players in Human Fertility and Reproductive System Cancers

Contact Info

Product

Resources

About